The immunogenicity and safety of the adjuvanted recombinant protein vaccine Sanofi/GSK-D614 or -B.1.351 administered as a heterologous booster dose

By | May 31, 2022
Researchers assessed the safety and immunogenicity of SARS-CoV-2 booster vaccines.